WO2008049881A2 - Polypeptides and pharmaceutical compositions comprising the same for the prevention and treatment of complications associated with infectious diseases - Google Patents
Polypeptides and pharmaceutical compositions comprising the same for the prevention and treatment of complications associated with infectious diseases Download PDFInfo
- Publication number
- WO2008049881A2 WO2008049881A2 PCT/EP2007/061466 EP2007061466W WO2008049881A2 WO 2008049881 A2 WO2008049881 A2 WO 2008049881A2 EP 2007061466 W EP2007061466 W EP 2007061466W WO 2008049881 A2 WO2008049881 A2 WO 2008049881A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- vwf
- polypeptide
- polypeptide according
- infectious diseases
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- Polypeptides and pharmaceutical compositions comprising the same for the prevention and treatment of complications associated with infectious diseases
- the present invention relates to polypeptides and pharmaceutical preparations that can be used in the prevention and treatment of complications associated with infectious diseases.
- Infectious diseases give rise to complications that are caused by an activation of the coagulation cascade, varying from subclinical activation (which is indicated by a rise in laboratory markers for thrombin and fibrin generation) to severe thrombocytopenia, or even thrombotic thrombocytopenic purpura (TTP) or disseminated intravascular coagulation (DIC) (Levi et al., JAMA, 270: 975-979 (1993)).
- subclinical activation which is indicated by a rise in laboratory markers for thrombin and fibrin generation
- TTP thrombotic thrombocytopenic purpura
- DI disseminated intravascular coagulation
- vWF von Willebrand Factor
- polypeptides comprising or essentially consisting of at least one Nanobody® directed against vWF and pharmaceutical compositions comprising the same can be used in the prevention and treatment of complications associated with infectious diseases.
- NanobodiesTM and polypeptides arc for example described in WO 04062551 and non-prepublished co-pending US provisional application 60/683,474 entitled 'Improved NanobodiesTM for the treatment of aggregation -mediated disorders' (filing date: May 20 lh 2005).
- the present invention therefore relates to the use of polypeptides directed against v WF for the preparation of a medicament for the prevention and/or treatment of complications associated with and/or caused by infectious diseases.
- the present invention relates to the use of polypeptides which competitively inhibit the interaction of vWF to gplb for the preparation of a medicament for the prevention and/or treatment of complications associated with and/or caused by infectious diseases.
- polypeptides used in the present invention comprise or essentially consist of at least one immunoglobulin sequence or immunoglobulin fragment.
- immunoglobulin sequences or immunoglobulin fragments are Fab fragments, F(ab') fragments, F(ab 2 ) fragments, Fv fragments, scFv fragments.
- polypeptides used in the present invention comprise or essentially consist of at least one immunoglobulin variable domain.
- polypeptides used in the present invention comprise or essentially consist of at least one single domain antibody.
- polypeptides used in the present invention comprise or essentially consist of at least one Nanobody®.
- Polypeptides that are specifically preferred for use in the present invention are described in WO04062551 and non-prepublished co-pending US provisional application 60/683,474 entitled 'Improved NanobodiesTM for the treatment of aggregation-mediated disorders' (filing date: May 20 th 2005). More preferred for use in the present invention are polypeptides directed against the Al domain of vWF and in particular the Al domain of activated vWF and/or the A3 domain of vWF as described in WO 04062551 and in non-prepublished co-pending US provisional application 60/683,474 entitled 'Improved NanobodiesTM for the treatment of aggregation-mediated disorders' (filing date: May 20 th 2005).
- NanobodiesTM directed against vWF are NanobodiesTM directed against vWF as described in non-prepublished co-pending US provisional application 60/683,474 entitled 'Improved NanobodiesTM for the treatment of aggregation-mediated disorders' (filing date: May 20 ih 2005).
- the present invention furthermore relates to the use of pharmaceutical preparations comprising at least one polypeptide as described above for the prevention and/or treatment of complications associated with and/or caused by infectious diseases.
- Such pharmaceutical compositions may for example be as described in WO 04062551 and non- prepublished co-pending US provisional application 60/683,474 entitled 'Improved NanobodiesTM for the treatment of aggregation-mediated disorders' (filing date: May 20 ⁇ 2005).
- Polypeptides, pharmaceutical compositions, and uses that are preferred according WO 04062551 and in the non-prepublished co ⁇ pending US provisional application 60/683,474 entitled 'Improved NanobodiesTM for the treatment of aggregation-mediated disorders' (filing date: May 20 th 2005) are also preferred for use in the present invention.
- polypeptides and pharmaceutical compositions comprising bivalent NanobodiesTM as described in WO 04062551 and in the non-prepublished co-pending US provisional application 60/683,474 entitled 'Improved NanobodiesTM for the treatment of aggregation-mediated disorders' (filing date: May 20 th 2005) may be used in the present invention.
- Polypeptides and pharmaceutical preparations of the present invention generally can be used in the prevention and treatment of the complications of infectious diseases.
- infectious diseases include but are not limited to sepsis, hemorrhagic fevers, malaria, AIDS, endotoxemia, leptospirosis, gastroenteritis, rheumatoid arthritis, viral diarrheas, viral pneumonia, influenza, hepatitis, viral leukemia, heipes, cytomegalovirus infection, infectious mononucleosis, and other diseases caused by bacterial or nonbacterial infectious pathogens, as will be clear to the skilled person.
- Complications of such infectious diseases that can be prevented or treated using the methods of the present invention include but are not limited to thrombocytopenia, disseminated intravascular coagulation (DIC), hemolytic uremic syndrome (HUS), thrombotic thrombocytopenic purpura (TTP), vasculitis, and other thrombohemorrhagic complications or syndromes, as will again be clear to the skilled person.
- Example 1 Clinical course of healthy humans after exposure to P. falciparum- infected mosquitoes and determination of platelet number
- Figure 1 shows that the quantitative nucleic acid sequence- based amplification (QT-NASBA; Schoone, G. J., L. Oskam, N, C. M. Kroon, H. D. F. H. Schallig, and S. A. Omar. 2000. Detection and quantification of Plasmodium falciparum in blood samples using quantitative nucleic acid sequence-based amplification. J. Ciin, Microbiol. 38:4072-4075) became positive after a median time of 7.0 days (range 6.0 to 9.0 days) post-infection and showed increasing parasitemia before the initiation of antimalarial treatment.
- QT-NASBA quantitative nucleic acid sequence- based amplification
- Treatment was started after a median time of 9.65 days (range 7.3 to 11.3) immediately upon microscopic detection of P. falciparum parasites in a thick blood smear.
- Figure 2 shows a decline in platelet count almost instantly after the onset of blood-stage infection and reached a nadir of 58.6% (95%CI 46.8-70.4%) of baseline level.
- Successful antimalarial treatment was followed by a recovery of the platelet count to a maximum mean value of 142% (95%CI 130.2-154.4%) of baseline level at day 21 postinfection before returning to baseline level at day 42. Hemoglobin levels remained unchanged throughout the infection.
- Figure 3 A shows the time course of vWF in the fourteen P. falcipa rum-infected human patients.
- vWF levels started to increase almost immediately after onset of blood- stage infection and reached a mean peak level of 190% above baseline. The range of individual peak levels was 115 to 385% above baseline.
- vWF-propeptide followed a similar kinetic pattern with a maximum mean peak level of 238% above baseline and with individual peak levels ranging from 129 to 291% above baseline (Figure 3B).
- the amounts of active vWF were determined at three time points during the infection: (1) baseline, (2) the day with the first significant decrease in platelet count, defined as a decrease of at least 2OxIO 9 platelets/liter compared to the previous day, and (3) the day with the lowest platelet count.
- the baseline level was set to be 1 for each patient
- the mean relative vWF activation factor was 1.5 (95% CI ⁇ .0-2.0) at the day of the first decrease in platelets and 2.3 (95% CI 1.2- 3.3) at the day of platelet count nadir.
- Figure 6 compares the kinetics of relative vWF levels with plasma CRP and interleukin (IL)- Ira levels, both representative markers of inflammation.
- the initial increase in vWF was not preceded by an increase in either CRP or IL- Ira.
- the proinflammatory cytokines tumor necrosis factor- ⁇ and IL- Ira did not show a significant increment throughout the infection.
- FIG 1 Kinetics of P. falciparum parasitemia before anti-malarial treatment. 14 healthy humans were experimentally infected with P. falciparum. Data are mean (+/ ⁇ SEM) parasitemia before antimalarial treatment as determined by QT-NASBA. The numbers of humans tested at indicated time points are included between brackets.
- FIG. 2 Kinetics of platelet count in P. falciparum blood-stage infection. 14 healthy humans were experimentally infected with P. falciparum. Data are the mean (+/- SEM) of relative (% of baseline) platelet counts during blood stage infection (* mean of 10 humans; ** mean of 8 humans). The mean absolute platelet count at baseline was 249x1.0 9 platelets/liter (95% CI 222-276xl0 9 ). Changes in relative platelet counts throughout the ' infection were significant (p ⁇ 0.0001 ; repeated measures ANOVA).
- FIG. 3 Kinetics of vWF and vWF-propeptide in P. falciparum blood-stage infection. 14 healthy humans were experimentally infected with P, falciparum. Data presented are the mean (+/- SEM) of relative levels of vWF (a) and vWF-propeptide (b) during the b ⁇ ood- stage infection until 2 days after initiation of antimalarial treatment (* mean of 1 1 humans; ** mean of 4 humans). Mean absolute baseline levels of vWF and propeptide were 35.3 nM (95%CI 26.5-44.0) and 5.8nM (95%CI 5.1-6.6), respectively.
- vWF-activation factor in P. falciparum blood-stage infection 14 healthy humans were experimentally infected with P. falciparum. Data are the vWF activation factors at three time points: 1) baseline, (2) the day with the first significant decrease in platelet count (>20xl0 9 platelets/liter), and (3) the day of platelet count nadir. The activation factor at baseline was set to be 1 for each human (Repeated measures ANOVA).
- Figure 5 Correlations between platelet count, vWF and vWF-activation factor. 14 healthy humans were experimentally infected with P. falciparum.
- A Daily vWF levels against corresponding platelet counts during blood-stage infection;
- B vWF levels against platelet counts at the day of platelet count nadir;
- C vWF activation factors against platelet counts at the day of platelet count nadir.
- FIG. 6 Comparisons between kinetics of CRP, IL-lra, and vWF. 14 healthy humans were experimentally infected with P. falciparum. Data represent the mean (+/-SEM) of plasma levels of CRP (A) and IL-lra (B) plotted against the mean (+/-SEM) of relevant vWF levels during the first days of blood-stage infection.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention relates to the use of polypeptides directed against (von Willebrand Factor) for the preparation of a medicament for the prevention and/or treatment of complications associated with and/or caused by infectious diseases, e.g. thrqmbohemorrhagic complications. More specifically, the present invention relates to the use of polypeptides which competitively inhibit the interaction of vWF to gplb for the preparation of a medicament for the prevention and/or treatment of complications associated with and/or caused by infectious diseases.
Description
Polypeptides and pharmaceutical compositions comprising the same for the prevention and treatment of complications associated with infectious diseases
The present invention relates to polypeptides and pharmaceutical preparations that can be used in the prevention and treatment of complications associated with infectious diseases.
Infectious diseases give rise to complications that are caused by an activation of the coagulation cascade, varying from subclinical activation (which is indicated by a rise in laboratory markers for thrombin and fibrin generation) to severe thrombocytopenia, or even thrombotic thrombocytopenic purpura (TTP) or disseminated intravascular coagulation (DIC) (Levi et al., JAMA, 270: 975-979 (1993)). Vascular endothelial injury, caused by the pathogen, is considered as one of the primary events in these complications, which, as shown in recent studies, may lead to excessive release of extremely large polymers of von Willebrand Factor (vWF) that cannot be processed to smaller forms because of an insufficient availability of vWF-cleaving melalloprotease. Recent data Jed to the hypothesis that patients with acute, sporadic thrombocytopenic disorders (e.g., occurring as complications associated with infectious diseases) have antibody-mediated inhibition of the plasma metal loprotease (Tsai et al., N Engl J Med, 339: 1585-1594 (1998); Mannucci et al., Blood. 74: 978-983 (1989)). Next to bacterial pathogens, activation of the coagulation system via this mechanism has been documented for viruses causing hemorrhagic fevers (HFs) (Bhamarapravati et al., Rev Infect Pis, l l(suppl): S826- 829 (1989); Heller et al., Thromb Haemost, 73: 368-373 (1995)), protozoa (such as the intraerythrocytic protozoa of the genus Plasmodium causing malaria) (Clemens et al., Br J Haematol. 87: 100-105 (1994); Mohanty et al., Am J Haematol. 54: 23-29 (1997)), and fungi (Fera et al., Infection, 21: 171-173 (1993)). Since no specific treatment is yet available for thrombocytopenic disorders such as TTP or DIC, therapy focuses on the treatment of the underlying disease (e.g., antibiotics for bacterial infection). However, for many infectious diseases, such as viral HF7 causal therapy is not available, and only supportive care can be provided.
Accordingly, there is a need for novel therapeutic agents that can be used in the prevention and treatment of complications associated with infectious diseases.
It has now been found that polypeptides directed against vWF and pharmaceutical compositions comprising the same can be used in the prevention and treatment of complications associated with infectious diseases.
More in particular, it has been found that polypeptides comprising or essentially consisting of at least one Nanobody® directed against vWF and pharmaceutical compositions comprising the same can be used in the prevention and treatment of complications associated with infectious diseases.
Such Nanobodies™ and polypeptides arc for example described in WO 04062551 and non-prepublished co-pending US provisional application 60/683,474 entitled 'Improved Nanobodies™ for the treatment of aggregation -mediated disorders' (filing date: May 20lh 2005).
The present invention therefore relates to the use of polypeptides directed against v WF for the preparation of a medicament for the prevention and/or treatment of complications associated with and/or caused by infectious diseases.
More specifically, the present invention relates to the use of polypeptides which competitively inhibit the interaction of vWF to gplb for the preparation of a medicament for the prevention and/or treatment of complications associated with and/or caused by infectious diseases.
Preferably the polypeptides used in the present invention comprise or essentially consist of at least one immunoglobulin sequence or immunoglobulin fragment. Examples of such immunoglobulin sequences or immunoglobulin fragments are Fab fragments, F(ab') fragments, F(ab2) fragments, Fv fragments, scFv fragments.
More preferably, the polypeptides used in the present invention comprise or essentially consist of at least one immunoglobulin variable domain.
Still more preferably, the polypeptides used in the present invention comprise or essentially consist of at least one single domain antibody.
Most preferably, the polypeptides used in the present invention comprise or essentially consist of at least one Nanobody®.
Polypeptides that are specifically preferred for use in the present invention are described in WO04062551 and non-prepublished co-pending US provisional application 60/683,474 entitled 'Improved Nanobodies™ for the treatment of aggregation-mediated disorders' (filing date: May 20th 2005).
More preferred for use in the present invention are polypeptides directed against the Al domain of vWF and in particular the Al domain of activated vWF and/or the A3 domain of vWF as described in WO 04062551 and in non-prepublished co-pending US provisional application 60/683,474 entitled 'Improved Nanobodies™ for the treatment of aggregation-mediated disorders' (filing date: May 20th 2005).
Most preferred for use in the present invention are Nanobodies™ directed against vWF as described in non-prepublished co-pending US provisional application 60/683,474 entitled 'Improved Nanobodies™ for the treatment of aggregation-mediated disorders' (filing date: May 20ih 2005).
The present invention furthermore relates to the use of pharmaceutical preparations comprising at least one polypeptide as described above for the prevention and/or treatment of complications associated with and/or caused by infectious diseases. Such pharmaceutical compositions may for example be as described in WO 04062551 and non- prepublished co-pending US provisional application 60/683,474 entitled 'Improved Nanobodies™ for the treatment of aggregation-mediated disorders' (filing date: May 20^ 2005).
Polypeptides, pharmaceutical compositions, and uses that are preferred according WO 04062551 and in the non-prepublished co~pending US provisional application 60/683,474 entitled 'Improved Nanobodies™ for the treatment of aggregation-mediated disorders' (filing date: May 20th 2005) are also preferred for use in the present invention. In particular, polypeptides and pharmaceutical compositions comprising bivalent Nanobodies™ as described in WO 04062551 and in the non-prepublished co-pending US provisional application 60/683,474 entitled 'Improved Nanobodies™ for the treatment of aggregation-mediated disorders' (filing date: May 20th 2005) may be used in the present invention.
Polypeptides and pharmaceutical preparations of the present invention generally can be used in the prevention and treatment of the complications of infectious diseases.
Such infectious diseases include but are not limited to sepsis, hemorrhagic fevers, malaria, AIDS, endotoxemia, leptospirosis, gastroenteritis, rheumatoid arthritis, viral diarrheas, viral pneumonia, influenza, hepatitis, viral leukemia, heipes, cytomegalovirus infection, infectious mononucleosis, and other diseases caused by bacterial or nonbacterial infectious pathogens, as will be clear to the skilled person. Complications of such
infectious diseases that can be prevented or treated using the methods of the present invention include but are not limited to thrombocytopenia, disseminated intravascular coagulation (DIC), hemolytic uremic syndrome (HUS), thrombotic thrombocytopenic purpura (TTP), vasculitis, and other thrombohemorrhagic complications or syndromes, as will again be clear to the skilled person.
Reference is for example made to the prior art mentioned above and to the further references cited therein.
EXAMPLES
Example 1: Clinical course of healthy humans after exposure to P. falciparum- infected mosquitoes and determination of platelet number
After fourteen healthy humans were exposed to P. falc iparum-m' f ected mosquitoes, they all became parasitemic. Figure 1 shows that the quantitative nucleic acid sequence- based amplification (QT-NASBA; Schoone, G. J., L. Oskam, N, C. M. Kroon, H. D. F. H. Schallig, and S. A. Omar. 2000. Detection and quantification of Plasmodium falciparum in blood samples using quantitative nucleic acid sequence-based amplification. J. Ciin, Microbiol. 38:4072-4075) became positive after a median time of 7.0 days (range 6.0 to 9.0 days) post-infection and showed increasing parasitemia before the initiation of antimalarial treatment. Treatment was started after a median time of 9.65 days (range 7.3 to 11.3) immediately upon microscopic detection of P. falciparum parasites in a thick blood smear. Figure 2 shows a decline in platelet count almost instantly after the onset of blood-stage infection and reached a nadir of 58.6% (95%CI 46.8-70.4%) of baseline level. Successful antimalarial treatment was followed by a recovery of the platelet count to a maximum mean value of 142% (95%CI 130.2-154.4%) of baseline level at day 21 postinfection before returning to baseline level at day 42. Hemoglobin levels remained unchanged throughout the infection.
Example 2: Time course of vWF, vWF-propeptide and active vWF
Figure 3 A shows the time course of vWF in the fourteen P. falcipa rum-infected human patients. vWF levels started to increase almost immediately after onset of blood- stage infection and reached a mean peak level of 190% above baseline. The range of
individual peak levels was 115 to 385% above baseline. vWF-propeptide followed a similar kinetic pattern with a maximum mean peak level of 238% above baseline and with individual peak levels ranging from 129 to 291% above baseline (Figure 3B). With the use of the Nanobody® AU/VWF-al 1, which specifically recognizes the Gplb-binding conformation of the vWF Al domain, the amounts of active vWF were determined at three time points during the infection: (1) baseline, (2) the day with the first significant decrease in platelet count, defined as a decrease of at least 2OxIO9 platelets/liter compared to the previous day, and (3) the day with the lowest platelet count. As shown in figure 4, when the baseline level was set to be 1 for each patient, the mean relative vWF activation factor was 1.5 (95% CI ϊ.0-2.0) at the day of the first decrease in platelets and 2.3 (95% CI 1.2- 3.3) at the day of platelet count nadir.
Example 3: ADAMTS-13 activity
To determine whether a decrease in ADAMTS-13 activity could account for the increased levels of (active) vWF, we quantitatively measured this ADAMTS-13 activity at baseline and at day 8 post-infection in the fourteen P. falciparum-infecled human patients. The mean ADAMTS-13 activity at day 8 postinfection was 99.9% (range 83-127%) of baseline activity. Therefore, the elevated levels of (active) vWF could not be explained by decreased proteolysis of large vWF multimers.
Example 4: Relation between (active) vWF, platelet count and parasitemia
To examine the relationship between platelet count, vWF and vWF activation factor, we plotted the relative values of these variables against each other. A strong inverse relationship (Pearson r= -0.62, p<0.0001) was present between vWF levels and platelet counts during the course of the infection (figure 5A). A similar strong association (Pearson's r=-0.61 , p=0.021) was found between vWF levels and platelet counts at the day of platelet count nadir (figure 5B). Moreover, vWF activation factor at that day related significantly (Pearson r=-0.58; p=0.03) to the relative platelet count as well (figure 5C). The degree of parasitemia (expressed as log number of parasites per milliliter blood) from the onset of parasitemia until the start of antimalarial treatment, correlated weakly (Pearson v= 0.3741; p=O.OO35) with corresponding relative vWF levels.
Example 5: Time course of cytokines and C-reactive protein
Figure 6 compares the kinetics of relative vWF levels with plasma CRP and interleukin (IL)- Ira levels, both representative markers of inflammation. The initial increase in vWF was not preceded by an increase in either CRP or IL- Ira. The proinflammatory cytokines tumor necrosis factor-α and IL- Ira did not show a significant increment throughout the infection.
FIGURES
Figure 1: Kinetics of P. falciparum parasitemia before anti-malarial treatment. 14 healthy humans were experimentally infected with P. falciparum. Data are mean (+/~ SEM) parasitemia before antimalarial treatment as determined by QT-NASBA. The numbers of humans tested at indicated time points are included between brackets.
Figure 2: Kinetics of platelet count in P. falciparum blood-stage infection. 14 healthy humans were experimentally infected with P. falciparum. Data are the mean (+/- SEM) of relative (% of baseline) platelet counts during blood stage infection (* mean of 10 humans; ** mean of 8 humans). The mean absolute platelet count at baseline was 249x1.09 platelets/liter (95% CI 222-276xl09). Changes in relative platelet counts throughout the ' infection were significant (p<0.0001 ; repeated measures ANOVA).
Figure 3: Kinetics of vWF and vWF-propeptide in P. falciparum blood-stage infection. 14 healthy humans were experimentally infected with P, falciparum. Data presented are the mean (+/- SEM) of relative levels of vWF (a) and vWF-propeptide (b) during the bϊood- stage infection until 2 days after initiation of antimalarial treatment (* mean of 1 1 humans; ** mean of 4 humans). Mean absolute baseline levels of vWF and propeptide were 35.3 nM (95%CI 26.5-44.0) and 5.8nM (95%CI 5.1-6.6), respectively. Changes in both vWF and vWF propeptide during the course of the infection were significant (p<0.0001; repeated measures ANOVA).
Figure 4: vWF-activation factor in P. falciparum blood-stage infection, 14 healthy humans were experimentally infected with P. falciparum. Data are the vWF activation factors at three time points: 1) baseline, (2) the day with the first significant decrease in platelet count (>20xl09 platelets/liter), and (3) the day of platelet count nadir. The activation factor at baseline was set to be 1 for each human (Repeated measures ANOVA).
Figure 5: Correlations between platelet count, vWF and vWF-activation factor. 14 healthy humans were experimentally infected with P. falciparum. (A) Daily vWF levels against corresponding platelet counts during blood-stage infection; (B) vWF levels against platelet counts at the day of platelet count nadir; (C) vWF activation factors against platelet counts at the day of platelet count nadir.
Figure 6: Comparisons between kinetics of CRP, IL-lra, and vWF. 14 healthy humans were experimentally infected with P. falciparum. Data represent the mean (+/-SEM) of plasma levels of CRP (A) and IL-lra (B) plotted against the mean (+/-SEM) of relevant vWF levels during the first days of blood-stage infection.
Claims
1. Use of a polypeptide directed against von Willebrand Factor (vWF) for the preparation of a medicament for the prevention or treatment of complications associated with infectious diseases.
2. Use of a polypeptide according to claim 1, wherein said polypeptide competitively inhibits the interaction of vWF to gplb.
3. Use of a polypeptide according to claim 1 or 2, wherein said polypeptide is directed against the Al domain of activated vWF and/or the A3 domain of vWF.
4. Use of a polypeptide according to any of claims 1 to 3, wherein said polypeptide comprises or essentially consists of at least one immunoglobulin sequence or immunoglobulin fragment
5. Use of a polypeptide according Io any of claims 1 to 4, wherein said polypeptide comprises or essentially consists of at least one immunoglobulin variable domain.
6. Use of a polypeptide according to any of claims 1 to 5, wherein said polypeptide comprises or essentially consists of at least one single domain antibody.
7. Use of a polypeptide according to any of claims 1 to 6, wherein said polypeptide comprises or essentially consists of at least one Nanobody®.
8. Use of a polypeptide according to any of claims 1 to 7, wherein said complications are chosen from the group consisting of thrornbohemorrhagic complications.
9. Use of a polypeptide according to claim 8, wherein said thrombohemorrhagic complications are chosen from the group consisting of thrombocytopenia, disseminated intravascular coagulation (DIC), hemolytic uremic syndrome (HUS), thrombotic thrombocytopenic purpura (TTP), or vasculitis.
10. Use of a polypeptide according to any of claims 1 to 9, wherein said infectious diseases are chosen from the group consisting of diseases caused by bacterial or non-bacterial infectious pathogens.
11. Use of a polypeptide according to claim 10, wherein said infectious diseases are chosen from the group consisting of sepsis, hemorrhagic fevers, malaria, AIDS, endotoxemia, leptospirosis, gastroenteritis, rheumatoid arthritis, viral diarrheas, viral pneumonia, influenza, hepatitis, viral leukemia, herpes, cytomegalovirus infection, infectious mononucleosis.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US85423606P | 2006-10-25 | 2006-10-25 | |
US60/854,236 | 2006-10-25 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2008049881A2 true WO2008049881A2 (en) | 2008-05-02 |
WO2008049881A3 WO2008049881A3 (en) | 2008-06-26 |
Family
ID=39295745
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2007/061466 WO2008049881A2 (en) | 2006-10-25 | 2007-10-25 | Polypeptides and pharmaceutical compositions comprising the same for the prevention and treatment of complications associated with infectious diseases |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2008049881A2 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1836500B1 (en) * | 2005-01-14 | 2010-07-07 | Ablynx N.V. | METHODS AND ASSAYS FOR DISTINGUISHING BETWEEN DIFFERENT FORMS OF DISEASES AND DISORDERS CHARACTERIZED BY THROMBOCYTOPENIA AND/OR BY SPONTANEOUS INTERACTION BETWEEN VON WILLEBRAND FACTOR (vWF) AND PLATELETS |
US7771724B2 (en) | 2002-08-07 | 2010-08-10 | Ablynx N.V. | Modulation of platelet adhesion based on the surface-exposed beta-switch loop of platelet glycoprotein IB-alpha |
US7807162B2 (en) | 2005-05-20 | 2010-10-05 | Ablynx N.V. | Single domain VHH antibodies against von Willebrand factor |
US9028816B2 (en) | 2003-01-10 | 2015-05-12 | Ablynx N.V. | Polypeptides and polypeptide constructs comprising single domain antibodies directed against von Willebrand factor |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004062551A2 (en) * | 2003-01-10 | 2004-07-29 | Ablynx N.V. | RECOMBINANT VHH SINGLE DOMAIN ANTIBODY FROM CAMELIDAE AGAINST VON WILLEBRAND FACTOR (vWF) OR AGAINST COLLAGEN |
US20050136056A1 (en) * | 2002-07-29 | 2005-06-23 | Shunsuke Kageyama | Pharmaceutical composition for the treatment of thrombocytopenia |
WO2006074947A2 (en) * | 2005-01-14 | 2006-07-20 | Ablynx N.V. | METHODS AND ASSAYS FOR DISTINGUISHING BETWEEN DIFFERENT FORMS OF DISEASES AND DISORDERS CHARACTERIZED BY THROMBOCYTOPENIA AND/OR BY SPONTANEOUS INTERACTION BETWEEN VON WILLEBRAND FACTOR (vWF) AND PLATELETS |
WO2006122825A2 (en) * | 2005-05-20 | 2006-11-23 | Ablynx Nv | Single domain vhh antibodies against von willebrand factor |
-
2007
- 2007-10-25 WO PCT/EP2007/061466 patent/WO2008049881A2/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050136056A1 (en) * | 2002-07-29 | 2005-06-23 | Shunsuke Kageyama | Pharmaceutical composition for the treatment of thrombocytopenia |
WO2004062551A2 (en) * | 2003-01-10 | 2004-07-29 | Ablynx N.V. | RECOMBINANT VHH SINGLE DOMAIN ANTIBODY FROM CAMELIDAE AGAINST VON WILLEBRAND FACTOR (vWF) OR AGAINST COLLAGEN |
WO2006074947A2 (en) * | 2005-01-14 | 2006-07-20 | Ablynx N.V. | METHODS AND ASSAYS FOR DISTINGUISHING BETWEEN DIFFERENT FORMS OF DISEASES AND DISORDERS CHARACTERIZED BY THROMBOCYTOPENIA AND/OR BY SPONTANEOUS INTERACTION BETWEEN VON WILLEBRAND FACTOR (vWF) AND PLATELETS |
WO2006122825A2 (en) * | 2005-05-20 | 2006-11-23 | Ablynx Nv | Single domain vhh antibodies against von willebrand factor |
Non-Patent Citations (1)
Title |
---|
DE MAST QUIRIJN ET AL: "Thrombocytopenia and release of activated von Willebrand factor during early Plasmodium falciparum malaria" JOURNAL OF INFECTIOUS DISEASES, vol. 196, no. 4, August 2007 (2007-08), pages 622-628, XP008090842 ISSN: 0022-1899 * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7771724B2 (en) | 2002-08-07 | 2010-08-10 | Ablynx N.V. | Modulation of platelet adhesion based on the surface-exposed beta-switch loop of platelet glycoprotein IB-alpha |
US9028816B2 (en) | 2003-01-10 | 2015-05-12 | Ablynx N.V. | Polypeptides and polypeptide constructs comprising single domain antibodies directed against von Willebrand factor |
US10112989B2 (en) | 2003-01-10 | 2018-10-30 | Ablynx, N.V. | Polypeptides and polypeptide constructs comprising single domain antibodies directed against von Willebrand factor |
US11034755B2 (en) | 2003-01-10 | 2021-06-15 | Ablynx N.V. | Polypeptides and polypeptide constructs comprising single domain antibodies directed against von willebrand factor |
EP1836500B1 (en) * | 2005-01-14 | 2010-07-07 | Ablynx N.V. | METHODS AND ASSAYS FOR DISTINGUISHING BETWEEN DIFFERENT FORMS OF DISEASES AND DISORDERS CHARACTERIZED BY THROMBOCYTOPENIA AND/OR BY SPONTANEOUS INTERACTION BETWEEN VON WILLEBRAND FACTOR (vWF) AND PLATELETS |
US7939277B2 (en) | 2005-01-14 | 2011-05-10 | Umc Utrecht Holding Bv | Methods and assays for distinguishing between different forms of diseases and disorders characterized by thrombocytopenia and/or by spontaneous interaction between Von Willebrand Factor (vWF) and platelets |
US7807162B2 (en) | 2005-05-20 | 2010-10-05 | Ablynx N.V. | Single domain VHH antibodies against von Willebrand factor |
US8372398B2 (en) | 2005-05-20 | 2013-02-12 | Ablynx N.V. | Single domain VHH antibodies against Von Willebrand Factor |
Also Published As
Publication number | Publication date |
---|---|
WO2008049881A3 (en) | 2008-06-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Heron et al. | HIV infection and compromised mucosal immunity: oral manifestations and systemic inflammation | |
Keyel | How is inflammation initiated? Individual influences of IL-1, IL-18 and HMGB1 | |
Lenz et al. | Systemic inflammation after trauma | |
Wynn | Cellular and molecular mechanisms of fibrosis | |
Wang et al. | COVID-19: inflammatory profile | |
Marchesan et al. | Porphyromonas gingivalis oral infection exacerbates the development and severity of collagen-induced arthritis | |
Rogliani et al. | Canakinumab for the treatment of chronic obstructive pulmonary disease | |
WO2008049881A2 (en) | Polypeptides and pharmaceutical compositions comprising the same for the prevention and treatment of complications associated with infectious diseases | |
Amar et al. | Periodontal innate immune mechanisms relevant to atherosclerosis | |
JP5814851B2 (en) | Compositions and methods for systemic treatment of arthritis | |
Lee et al. | Elderly patients exhibit stronger inflammatory responses during gout attacks | |
Zhang et al. | Factors determining the formation and release of bioactive IL-12: regulatory mechanisms for IL-12p70 synthesis and inhibition | |
Masoomikarimi et al. | Advances in immunotherapy for COVID-19: A comprehensive review | |
Patel et al. | Therapeutic use of specific tumour necrosis factor inhibitors in inflammatory diseases including COVID-19 | |
Boff et al. | The chemokine fragment CXCL9 (74–103) diminishes neutrophil recruitment and joint inflammation in antigen-induced arthritis | |
Arshad et al. | Is COVID-19 fatality rate associated with malaria endemicity? | |
Oliveira et al. | Characterization of chronic cutaneous lesions from TNF‐receptor‐1‐deficient mice infected by Leishmania major | |
US20140299548A1 (en) | Selective Chemokine Modulation | |
Sørensen et al. | Blocking CC chemokine receptor (CCR) 1 and CCR5 during herpes simplex virus type 2 infection in vivo impairs host defence and perturbs the cytokine response | |
WO2007143545A2 (en) | Tnf signaling in myxoma virus treatments | |
JP2010522728A5 (en) | ||
Radwan et al. | Serum interleukin-17 expression in a group of Egyptian patients with juvenile systemic lupus erythematosus | |
Mansourabadi et al. | Intravenous immunoglobulin therapy in myocarditis | |
Kayongo et al. | Mechanisms of lung damage in tuberculosis: implications for chronic obstructive pulmonary disease | |
RU2536285C1 (en) | METHOD FOR PREVENTING DEVELOPING THROMBOCYTOPENIA IN PATIENTS SUFFERING CHRONIC HEPATITIS C COMBINED WITH Helicobacter pylori INFECTION AND RECEIVING COMBINED ANTIVIRAL THERAPY |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07821829 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 07821829 Country of ref document: EP Kind code of ref document: A2 |